BR112014011055A2 - novos derivados de [1,2,3]triazolo[4,5-d]pirimidina - Google Patents
novos derivados de [1,2,3]triazolo[4,5-d]pirimidinaInfo
- Publication number
- BR112014011055A2 BR112014011055A2 BR112014011055A BR112014011055A BR112014011055A2 BR 112014011055 A2 BR112014011055 A2 BR 112014011055A2 BR 112014011055 A BR112014011055 A BR 112014011055A BR 112014011055 A BR112014011055 A BR 112014011055A BR 112014011055 A2 BR112014011055 A2 BR 112014011055A2
- Authority
- BR
- Brazil
- Prior art keywords
- triazolo
- new
- pyrimidine derivatives
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
Abstract
resumo novos derivados de [1,2,3]triazolo[4,5-d]pirimidina a invenção se refere a um composto da fórmula (i): (i) nnnnnar2r1 em que a, r1 e r2 são definidos como na descrição e nas reivindicações. o composto da fórmula (i) pode ser usado como um medicamento nos agonistas do receptor de canabinóide 2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11188333.6 | 2011-11-08 | ||
EP11188333 | 2011-11-08 | ||
PCT/EP2012/071788 WO2013068306A1 (en) | 2011-11-08 | 2012-11-05 | [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014011055A2 true BR112014011055A2 (pt) | 2017-05-02 |
BR112014011055B1 BR112014011055B1 (pt) | 2022-01-11 |
Family
ID=47116003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014011055-7A BR112014011055B1 (pt) | 2011-11-08 | 2012-11-05 | Novos derivados de [1,2,3]triazolo[4,5-d]pirimidina |
Country Status (31)
Country | Link |
---|---|
US (2) | US8741906B2 (pt) |
EP (1) | EP2776442B1 (pt) |
JP (1) | JP6138141B2 (pt) |
KR (1) | KR102032337B1 (pt) |
CN (1) | CN103930426B (pt) |
AR (1) | AR088663A1 (pt) |
AU (1) | AU2012334173B2 (pt) |
BR (1) | BR112014011055B1 (pt) |
CA (1) | CA2850458C (pt) |
CL (1) | CL2014001174A1 (pt) |
CO (1) | CO6920295A2 (pt) |
CY (1) | CY1117147T1 (pt) |
DK (1) | DK2776442T3 (pt) |
EA (1) | EA023581B1 (pt) |
ES (1) | ES2553704T3 (pt) |
HK (1) | HK1194732A1 (pt) |
HR (1) | HRP20160052T1 (pt) |
HU (1) | HUE025543T2 (pt) |
IL (1) | IL231949A (pt) |
MX (1) | MX342309B (pt) |
MY (1) | MY170878A (pt) |
PE (1) | PE20141588A1 (pt) |
PL (1) | PL2776442T3 (pt) |
PT (1) | PT2776442E (pt) |
RS (1) | RS54436B1 (pt) |
SG (1) | SG11201402197UA (pt) |
SI (1) | SI2776442T1 (pt) |
TW (2) | TWI704150B (pt) |
UA (1) | UA111640C2 (pt) |
WO (1) | WO2013068306A1 (pt) |
ZA (1) | ZA201402905B (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA111640C2 (uk) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
US9067943B2 (en) * | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
HUE034831T2 (en) | 2013-03-07 | 2018-03-28 | Hoffmann La Roche | New pyrazole derivatives |
MX365921B (es) | 2013-03-26 | 2019-06-20 | Hoffmann La Roche | Nuevos derivados de piridina. |
WO2014177490A1 (en) | 2013-05-02 | 2014-11-06 | F. Hoffmann-La Roche Ag | Purine derivatives as cb2 receptor agonists |
EP2991988B1 (en) | 2013-05-02 | 2017-05-31 | F. Hoffmann-La Roche AG | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists |
UA116395C2 (uk) * | 2013-09-06 | 2018-03-12 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ |
NZ766530A (en) | 2014-08-04 | 2023-09-29 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
EA031735B1 (ru) * | 2014-11-07 | 2019-02-28 | Ф. Хоффманн-Ля Рош Аг | ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2 |
CN107743491B (zh) * | 2015-05-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物 |
CN105541738B (zh) * | 2016-01-21 | 2018-04-06 | 西北师范大学 | 一种三氮唑取代的苯乙酮类化合物的制备方法 |
SG11201809678VA (en) * | 2016-06-23 | 2018-11-29 | Hoffmann La Roche | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |
WO2017220516A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
JP6964099B2 (ja) | 2016-06-23 | 2021-11-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 新規[1,2,3]トリアゾロ[4,5−d]ピリミジン誘導体 |
CN109311895B (zh) | 2016-06-23 | 2021-06-18 | 豪夫迈·罗氏有限公司 | 新型[1,2,3]三唑并[4,5-d]嘧啶衍生物 |
WO2022011171A1 (en) * | 2020-07-08 | 2022-01-13 | Klotho Therapeutics, Inc. | Novel compounds and methods for increasing klotho gene expression |
CN113164830B (zh) * | 2018-08-20 | 2023-02-21 | 贝索制药有限责任公司 | 大麻素的制备方法 |
CA3138307A1 (en) | 2019-05-13 | 2020-11-19 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
WO2021198955A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
CA3174176A1 (en) | 2020-03-31 | 2021-10-07 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
KR20230112615A (ko) | 2020-11-23 | 2023-07-27 | 에프. 호프만-라 로슈 아게 | 테트라졸 유도체의 제조를 위한 신규 방법 |
AR127456A1 (es) | 2021-10-28 | 2024-01-24 | Hoffmann La Roche | Sintesis de [1,2,3]triazol[4,5-d]pirimidinas |
WO2023237460A1 (en) | 2022-06-07 | 2023-12-14 | F. Hoffmann-La Roche Ag | A process for preparing 1-[5-tert-butyl-3-[(1-methyltetrazol-5 -yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol |
WO2024047079A1 (en) | 2022-09-01 | 2024-03-07 | F. Hoffmann-La Roche Ag | Anti-cb2 antibodies and their use in a flow cytometry assay to measure cell surface cb2 expression |
WO2024047078A1 (en) * | 2022-09-01 | 2024-03-07 | F. Hoffmann-La Roche Ag | Dosage regimen of vicasinabin |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4076711A (en) * | 1976-04-05 | 1978-02-28 | Schering Corporation | Triazolo [4,5-d]-pyrimidines |
US5204353A (en) * | 1987-04-07 | 1993-04-20 | Ciba-Geigy Corporation | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith |
NZ274978A (en) * | 1993-10-12 | 1998-04-27 | Du Pont Merck Pharma | 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof |
WO1995010506A1 (en) * | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
ES2384808T3 (es) | 2006-12-14 | 2012-07-12 | Bristol-Myers Squibb Company | Heterociclos azabicíclicos como moduladores de los receptores de cannabinoides |
US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
CA2717509A1 (en) * | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
AR080711A1 (es) * | 2010-03-31 | 2012-05-02 | Lilly Co Eli | Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor |
UA111640C2 (uk) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
US9067943B2 (en) * | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
-
2012
- 2012-05-11 UA UAA201406094A patent/UA111640C2/uk unknown
- 2012-11-05 MY MYPI2014701156A patent/MY170878A/en unknown
- 2012-11-05 CA CA2850458A patent/CA2850458C/en active Active
- 2012-11-05 KR KR1020147015045A patent/KR102032337B1/ko active IP Right Grant
- 2012-11-05 MX MX2014005184A patent/MX342309B/es active IP Right Grant
- 2012-11-05 PL PL12780208T patent/PL2776442T3/pl unknown
- 2012-11-05 PT PT127802080T patent/PT2776442E/pt unknown
- 2012-11-05 RS RS20150807A patent/RS54436B1/en unknown
- 2012-11-05 WO PCT/EP2012/071788 patent/WO2013068306A1/en active Application Filing
- 2012-11-05 PE PE2014000649A patent/PE20141588A1/es active IP Right Grant
- 2012-11-05 EA EA201490912A patent/EA023581B1/ru unknown
- 2012-11-05 SG SG11201402197UA patent/SG11201402197UA/en unknown
- 2012-11-05 HU HUE12780208A patent/HUE025543T2/en unknown
- 2012-11-05 AU AU2012334173A patent/AU2012334173B2/en active Active
- 2012-11-05 CN CN201280054639.7A patent/CN103930426B/zh active Active
- 2012-11-05 BR BR112014011055-7A patent/BR112014011055B1/pt active IP Right Grant
- 2012-11-05 JP JP2014540410A patent/JP6138141B2/ja active Active
- 2012-11-05 EP EP12780208.0A patent/EP2776442B1/en active Active
- 2012-11-05 SI SI201230368T patent/SI2776442T1/sl unknown
- 2012-11-05 ES ES12780208T patent/ES2553704T3/es active Active
- 2012-11-05 DK DK12780208.0T patent/DK2776442T3/en active
- 2012-11-06 AR ARP120104159A patent/AR088663A1/es active IP Right Grant
- 2012-11-06 US US13/669,610 patent/US8741906B2/en active Active
- 2012-11-07 TW TW106134768A patent/TWI704150B/zh active
- 2012-11-07 TW TW101141431A patent/TWI639600B/zh active
-
2014
- 2014-03-28 CO CO14067070A patent/CO6920295A2/es active IP Right Grant
- 2014-04-03 IL IL231949A patent/IL231949A/en active IP Right Grant
- 2014-04-11 US US14/250,781 patent/US9056866B2/en active Active
- 2014-04-22 ZA ZA2014/02905A patent/ZA201402905B/en unknown
- 2014-05-06 CL CL2014001174A patent/CL2014001174A1/es unknown
- 2014-08-06 HK HK14108045.2A patent/HK1194732A1/zh unknown
-
2016
- 2016-01-15 HR HRP20160052TT patent/HRP20160052T1/hr unknown
- 2016-01-19 CY CY20161100050T patent/CY1117147T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014011055A2 (pt) | novos derivados de [1,2,3]triazolo[4,5-d]pirimidina | |
BR112015012919A2 (pt) | novos derivados de piridina | |
BR112013031463A2 (pt) | piridina-2-amidas úteis como agonistas de cb2 | |
BR112014012479A2 (pt) | derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas das agonistas de receptor 2 de canabinóide | |
BR112015013124A2 (pt) | novos derivados de piridina | |
BR112015027394A8 (pt) | derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2 | |
BR112015020795A2 (pt) | derivados de pirazol novos | |
BR112015009600A2 (pt) | piridina-2-amidas úteis como agonistas cb2 | |
BR112012026338A2 (pt) | novos derivados de 3,3-dimetil tetrahidroquinolina | |
BRPI1013567B8 (pt) | Derivados de prolina como inibidores de catepsina | |
CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
BR112015009603A2 (pt) | novos derivados de pirazina | |
BR112015027396A2 (pt) | derivados de purina como agonistas do receptor de cb2 | |
BR112013023876A2 (pt) | derivados de pirroltriazinona como inibidores de pi3k | |
BR112015007231A2 (pt) | derivados de pirroltriazinona como inibidores de pi3k | |
BR112014010047A8 (pt) | novos derivados de pirazina | |
BR112015024272A2 (pt) | novos derivados de piridina | |
BR112012030473A2 (pt) | pesticidas baseados em derivados pirrolidina espiroheterocíclicos | |
BR112015023161A8 (pt) | derivados de piridin-4-ila | |
BR112012013119A2 (pt) | derivados de 1-amino-piperidina-pirrolidina-diona espirocondensada com atividade pesticida. | |
CO6741154A2 (es) | Compuestos de triazolopiridina | |
BR112018011562A2 (pt) | novos derivados de fenil | |
BR112014012521A2 (pt) | novos derivados de pirrolidina como inibidores de catepsina | |
BR112018075143A2 (pt) | derivados de [1,2,3] triazolo [4,5-d] pirimidina com afinidade para o receptor de canabonóide tipo 2 | |
BR112014019220A8 (pt) | Novos derivados de pirrolidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/11/2012, OBSERVADAS AS CONDICOES LEGAIS. |